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The anaphase-promoting complex (APC) is an essential E3
ubiquitin ligase responsible for catalyzing proteolysis of key reg-
ulatory proteins in the cell cycle. Cdh1 is a co-activator of the
APC aiding in the onset and maintenance of G1 phase, whereas
phosphorylation of Cdh1 at the end of G1 phase by cyclin-de-
pendent kinases assists in the inactivation of APCCdh1. Here, we
suggest additional components are involved in the inactivation
of APCCdh1 independent of Cdh1 phosphorylation. We have
identified proteins known as Acm1 and Bmh1, which bind and
forma ternary complexwithCdh1. The presence of phosphoryl-
ated Acm1 is critical for the ternary complex formation, and
Acm1 is predominantly expressed in S phase when APCCdh1 is
inactive. The assembly of the ternary complex inhibits ubiquiti-
nation of Clb2 in vitro by blocking the interaction of Cdh1 with
Clb2. In vivo, lethality caused by overexpression of constitu-
tively active Cdh1 is rescued by overexpression of Acm1. Par-
tially phosphorylatedCdh1 in the absence ofACM1 still binds to
andactivates theAPC.However, the additionofAcm1decreases
Clb2 ubiquitination when using either phosphorylated or non-
phosphorylated Cdh1. Taken together, our results suggest an
additional inactivation mechanism exists for APCCdh1 that is
independent of Cdh1 phosphorylation.
The eukaryotic cell cycle is largely controlled by targeted
proteolysis of regulatory proteins, specifically through ubiq-
uitin-mediated proteolysis (1–4). The anaphase-promoting
complex (APC)2 is an essential E3 ubiquitin ligase responsible
for catalyzing proteolysis of key regulatory proteins in the cell
cycle. Substrate specificity of the APC is attributed to co-acti-
vator proteins that associate with particular substrates
throughout the cell cycle (5–7). The co-activators Cdc20 and
Cdh1 are thought to aid in the recruitment of particular sub-
strates through substrate binding independent of the APC or in
assemblies known as APCCdc20 or APCCdh1 (8–10). The APC
polyubiquitinates substrates, marking them for degradation by
the proteasome (6, 11). Ubiquitin ligase activity of the APC has
been shown to require the presence of Cdc20 or Cdh1 (5,
11–14). Co-activators interact with the APC at specific times
during the cell cycle, with Cdc20 activating the APC from early
to lateMphase andCdh1 activating theAPC from lateMphase
through G1 (5, 12, 15).
Phosphorylation of Cdh1 has been demonstrated as an
important control mechanism for the APCCdh1 complex (16).
Phosphorylation of Cdh1 is cell cycle-dependent and is consid-
ered to be themain regulatorymechanism bywhichAPCCdh1 is
inactivated. Cdh1 is phosphorylated in S phase, G2, andmitosis
and dephosphorylated inG1 (16). The phosphorylation of Cdh1
corresponds to high levels of the cyclin-dependent kinase
(CDK) activity. When the CDK consensus phosphorylation
sites within Cdh1 from budding yeast were mutated to alanine,
Cdh1 activated the APC constitutively, failing to accumulate
mitotic cyclins (16). Cdh1 is phosphorylated at the G1/S phase
transition by G1 and S phase cyclins that activate the CDK in
budding yeast, Cdc28. Cdh1 remains hyperphosphorylated
until late inmitosiswhenCdc14 phosphatase is activated allow-
ing Cdh1 to reactivate the APC (15, 17). In S and M phases,
Cdh1 failed to associate with the APC in Cdh1 co-immunopre-
cipitations (16). Additionally, in vitro phosphorylation of
recombinant Cdh1 by CDKs is sufficient for inactivation of the
APC (18).
Protein-protein interactions have also been shown to be
important in the regulation of Cdh1 (19, 20). In higher
eukaryotes, Emi1 andMad2B have been shown to inhibit Cdh1
through protein-protein interactions (19, 20). Although the
function of Mad2B is unclear, Emi1 is reported to inhibit sub-
strate binding to Cdh1. However, similar inhibitors in yeast
have not yet been identified.
To discover potentially novel Cdh1 interacting proteins, we
performed a proteomic screen of Cdh1 immunoprecipitations
in budding yeast. In the process, we identified a multiprotein
complex that forms with Cdh1, consisting of a previously
uncharacterized protein Acm1 (YPL267W) and two members
of the 14-3-3 protein family known as Bmh1 and Bmh2. The
expression of Acm1 is cell cycle-dependent, and Acm1 is nec-
essary for complex formation with Cdh1 and Bmh1. Formation
of the complex, whichwe refer to as the CAB complex or Cdh1/
Acm1/Bmh1 complex, is restricted to the cell cycle window in
which Acm1 is expressed. Without Acm1, Clb2 levels in vivo
appear lower when compared with cells containing Acm1
under certain growth conditions. Complex formation inhibits
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APCCdh1 activity in vitro, and lethality caused by overexpres-
sion of constitutively active Cdh1 is rescued by Acm1 overex-
pression. The CAB complex functions to block substrate bind-
ing with the co-activator. Partially phosphorylated Cdh1
binds and activates the APC in the absence of Acm1. Lastly,
we have shown the ability of Acm1 and Bmh1 to inhibit
APCCdh1 despite the Cdh1 phosphorylation state. Taken
together, our data suggest the existence of an additional
inactivation mechanism of APCCdh1 independent of Cdh1
phosphorylation.
EXPERIMENTAL PROCEDURES
Cloning—Cloning for p415ADH-FLAGCdh1 and pNC219-
FLAGCdh1m9have been described previously (21). The result-
ing centromeric plasmid, p415ADH-FLAGCdh1, constitu-
tively expresses 3FLAG-CDH1 from the ADH promoter.
pNC219-FLAGCdh1m9 expresses the 3FLAG-CDH1 phos-
phomutant with 9 of 11 CDK sites mutated to alanine from the
GAL promoter. The plasmids pHLP117 expressing 3HA-Acm1
from its natural promoter, pHLP107 expressing FLAG-Acm1
from the ADH promoter, and pHLP106 expressing FLAG-
Acm1 from the GAL1 promoter were gifts from M. Hall. The
plasmids pRSETClb2, pET28-His6-Cdh1, and pET28-His6-
Ubc4 were gifts from D. Barford (22). BMH1 and CLB2 were
amplified by PCR from yeast genomic DNA and cloned into
pGEX-4T-1 at the BamH1 and XhoI sites yielding a GST tag on
the N terminus of Bmh1 and Clb2 for overexpression in Esche-
richia coli. All PCR-generated constructs were confirmed by
DNA sequencing.
Strains and Media—Yeast strains are described in Table 1.
Media were YPD (20 g/liter peptone (Fisher), 10 g/liter yeast
extract (Bacto), 20 g/liter dextrose (MP Biomedicals)), YP (20
g/liter peptone, 10 g/liter yeast extract) and synthetic medium
(6.7 g/liter yeast nitrogen base lacking amino acids (Difco), 20
g/liter dextrose, or 20 g/liter raffinose, appropriate amino acid
dropout mix (Q-Biogene)).
Cell Cycle Arrest—For G1 arrest in bar1 cells, -factor pep-
tide is added directly to the cultures during mid-log phase
growth at 50 g/liter. BAR1 cells require 3 g/ml -factor pep-
tide for an effective G1 arrest. Arresting in S phase requires the
addition of 10mg/ml hydroxyurea (Sigma).M phase arrests are
carried out by the addition of 15 mg/ml nocodazole (Sigma).
This laboratory has acquired a cdc15-2 yeast strain that allows
cell cycle arrest in telophase induced by temperature shift from
25 °C to 37 °C. Cell cycle arrests are monitored by phase-con-
trast microscopy until 90% of the cells have achieved the
desired morphology.
Cdh1 Purification—Yeast cells were grown asynchronously
toA600  1 and lysed in 1 volume of APC-C lysis buffer (25 mM
HEPES-NaOH, pH7.5, 400mMNaCl, 10% glycerol, 0.1%Triton
X-100, 0.1mM dithiothreitol, 0.5mM phenylmethylsulfonyl flu-
oride, and Complete protease inhibitor mixture (Roche
Applied Science)) by vortexing for 45 min at 4 °C in 1.7-ml
microcentrifuge tubes containing 0.5ml of 0.5-mm glass beads.
Cell lysate was cleared by centrifugation at 16,000  g for 15
min. Soluble extracts were pooled and cleared a second time at
5000 rpm for 5 min. Extracts were incubated with anti-FLAG
M2 antibody-coupled resin (Sigma) for 1.5 h at 4 °C. Bound
Cdh1 was washed extensively with APC-C buffer (25 mM
HEPES-NaOH, pH7.5, 400mMNaCl, 10% glycerol, 0.1%Triton
X-100, 0.1mM dithiothreitol, 0.5mM phenylmethylsulfonyl flu-
oride) and eluted 2with FLAGpeptide (250g/ml) in APC-C
buffer.
APC Purification—Yeast cells were grown and lysed, and
lysates were cleared in the same manner as for Cdh1. Extracts
from YNL172W-TAP were incubated with calmodulin affinity
resin (Stratagene) for 1.5 h at 4 °C inAPC-C buffer containing 1
mM CaCl2. Cells from YKA156 (2 liters) were grown to A600 
0.5 at 25 °C, and temperature was shifted to 37 °C for 2 h.
Extracts from YKA156 were incubated with EZView anti-
FLAG M2 antibody-coupled resin (Sigma) for 1.5 h at 4 °C,
washed extensively with APC-C buffer, and eluted 2 with
FLAG peptide (250 g/ml) in low salt APC-C buffer (25 mM
HEPES-NaOH, pH7.5, 150mMNaCl, 10% glycerol, 0.1%Triton
X-100, 0.1 mM dithiothreitol).
Acm1 Purification—Yeast cells were grown and lysed, and
lysates were cleared in the same manner as for Cdh1 purifica-
tions. Extracts from YPL267W-TAP were incubated with cal-
modulin affinity resin (Stratagene) for 1.5 h at 4 °C in APC-C
buffer containing 1 mM CaCl2. Acm1 bound to beads was used
in binding assays. Acm1 used in the ubiquitination assay and
Clb2 binding assay was eluted with TAP elution buffer (40 mM
Tris, pH 7.5, 0.6mM dithiothreitol, 2.5mMEDTA) for 30min at
room temperature while shaking at 700 rpm. MgCl2 was added
to the elution buffer at a final concentration of 15 mM. FLAG-
TABLE 1
S. cerevisiae strains used in this study
Strain Relevant genotype Source
W1588-4c MATa ade2-1 can1–100 His3–11 15 leu2–3 112 trp1-1 ura3-1 R. Rothstein
YKA150 W1588-4c bar1::URA3 Hall et al. (23)
YKA154 YKA150 CDH1-3FLAG::KanMX4 This study
YKA323 YKA150 ypl267w::KanMX4 This study
DLY3033 MATa bar1::URA3 cdc15-2 ura3 leu2 trp1 J. Pringle
YKA156 DLY3033 CDC27-3FLAG::KanMX4 This study
BY4741 MATa his3-D1 leu2-D0 met15-D0 ura3-D0 Open Biosystems
YPL267W-TAP BY4741 Acm1-TAP::HIS3MX6 Open Biosystems
YKA322 YPL267W-TAP cdh1::KanMX4 This study
YER177W-TAP BY4741 Bmh1 -TAP::HIS3MX6 Open Biosystems
YNL172W-TAP BY4741 APC1-TAP::HIS3MX6 Open Biosystems
YGL003C BY4741 cdh1::KanMX4 Open Biosystems
YPL267W BY4741 acm1::KanMX4 Open Biosystems
YER177W BY4741 bmh1::KanMX4 Open Biosystems
YDR099W BY4741 bmh2::KanMX4 Open Biosystems
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Acm1 used in the ubiquitination assay and binding assays was
purified in the same manner as APC.
Bmh1/Clb2 Purification—Overnight cultures of E. coli har-
boring BMH1 or CLB2 in the pGEX-4T-1 plasmid were grown
and used to inoculate 1 liter of 2XYT (16 g/liter Tryptone, 10
g/liter yeast extract, 5 g/literNaCl) containing 100g/ml ampi-
cillin. Cultures were grown for 8 h at 37 °C, temperature was
shifted to 23 °C, and isopropyl 1-thio--D-galactopyranoside
was added (100 M final contration). Cells were grown over-
night and harvested by centrifugation. The resulting cell pellet
was resuspended in 1 phosphate-buffered saline 0.5 M NaCl
keeping suspension on ice. Cells were lysed 3using sonication
for 20-s intervals with a 40-s pause. Lysates were cleared by
centrifugation at 4 °C and 25,000 rpm for 30 min. Cleared
lysates were incubated with 100 l of washed GSH beads (glu-
tathione-Sepharose 4B, Amersham Biosciences) for 10 min.
Beads and lysate were pipetted and transferred to Bio-Rad
micro columns. Beads were washed with 5 column volumes of
1 phosphate-buffered saline 0.5 M NaCl. Bound protein was
used on the GSH beads for binding assays. Bmh1 used in the
ubiquitination assay was treated with biotinylated thrombin
(Novagen) to cleave the GST tag. The sample was treated with
streptavidin-agarose to remove thrombin. Buffer was exchanged
with40mMTris,pH7.5,0.6mMdithiothreitol, 10mMMgCl2using
Microcon filters with a 10-kDa cutoff (Millipore).
In Vitro Binding Assays—Compact reaction columns (USB)
were used for all binding assays. Protein used as bait was immo-
bilized on affinity beads and washed in the reaction column.
Protein used as prey was added to each column and allowed to
incubate for times noted at 4 °C under rotation. Columns were
washed with five column volumes of APC-C lysis buffer and
eluted in 1 NuPAGE LDS sample buffer (Invitrogen) unless
the immobilized protein used the TAP tag. In TAP purifica-
tions, APC-C buffer containing 1 mM CaCl2 was used for
washes. Five percent of each reaction was loaded on the gel.
Ubiquitination Assay—Ubiquitination assays were carried
out as described by D. Barford (22). The substrate Clb2
(pRSETClb2), the co-activator Cdh1 (pET28-His6-Cdh1), and
the E2 Ubc4 (pET28-His6-Ubc4) were prepared using the TNT
T7 Quick-coupled in vitro transcription/translation kit (Pro-
mega) unless otherwise noted. APC (YKA156) and Acm1 were
purified from budding yeast (see APC and Acm1 purification),
whereas Bmh1 was expressed and purified from E. coli (see
Bmh1 purification). APC used in each reaction was 1/50th of
the elution from 2 liter of cells. Clb2 was radiolabeled with
[35S]methionine (PerkinElmer Life Sciences). Reactions were
run on a 4–12% Bis-Tris NuPAGE gel (Invitrogen), dried, and
imaged using Hyperfilm (Amersham Biosciences).
Flow Cytometry—Cells were prepared as described previ-
ously (23). DNA content was measured on a FACScan instru-
ment and ModFit LT software (Verity Software House, Inc.)
used to calculate percentages of G1, S, and G2/M cells present.
Protein Identification and Mass Spectrometry—Elutions
from Cdh1 purifications were acetone-precipitated, reconsti-
tuted in 1 LDS sample buffer containing 100 mM dithiothre-
itol, and separated on a 4–12% Bis-Tris NuPAGE gel (Invitro-
gen). Gels were stained with Coomassie Blue or silver. Protein
bands were excised, destained, and incubated with trypsin.
After digestion, samples were frozen, lyophilized, and resus-
pended in a small volume of 50% methanol/0.1% formic acid.
Peptide masses were analyzed on a matrix-assisted laser de-
sorption ionization-TOF/TOF mass spectrometer (Applied
Biosystems), and proteins were identified using the MASCOT
search engine (Matrix Science). Samples that needed further
analysis were analyzed on a nano-ESI Q-TOF (Micromass)
mass spectrometer (47).
Gel Filtration—FLAG immunoprecipitations were prepared
from S phase-arrested cells in APC-C buffer. The samples were
fractionated on a Superdex 200 HR 10/30 gel-filtration column
with extraction buffer on an AKTA Explorer system (Amer-
sham Biosciences) at 0.4 ml/min. Fractions were collected in
0.5-ml increments, and each fraction was acetone-precipitated.
Proteins were resolved by SDS-PAGE and detected by immu-
noblotting with an -FLAG antibody.
RESULTS
Acm1 and Bmh1 Associate with Cdh1 in Vivo and in Vitro
and Form a Ternary Complex—To identify potential interact-
ing proteins of Cdh1, we used a targeted proteomic approach
consisting of immunoprecipitations with genomically FLAG-
tagged Cdh1 followed by mass spectrometric analysis. We dis-
covered three proteins known as Acm1, Bmh1, and Bmh2 in
budding yeast, which stably interact with Cdh1 under high salt
wash conditions (Fig. 1A). The untagged parent strain was used
as a control. C-terminal Cdh1 fragments were also identified by
mass spectrometry. Interestingly, we did not identify any other
specific proteins in the Cdh1 immunoprecipitation presumably
due to the high salt wash conditions, which disrupt all but the
most stable protein complexes. Gel-filtration analysis of the
complex showed co-elution of Cdh1 and Acm1 in a stoichio-
metric interaction (data not shown). Acm1 (APCCdh1 modula-
tor 1) is a previously uncharacterized protein with no known
function, although it was originally identified as a potential
CDK substrate (24). However, as members of the 14-3-3 family
of proteins, Bmh1 and Bmh2 have been associated with a vari-
ety of cellular processes and have been defined as phospho-
serine-binding proteins (25, 26). We believe two possibilities
for these interactions exist, either as potential APCCdh1 sub-
strates or as regulators of Cdh1.
To confirm the specificity of the interactions between Cdh1,
Acm1, and Bmh1, we used in vitro binding assays. FLAG-
tagged Cdh1 and TAP-tagged Acm1 were purified from yeast
while recombinant Bmh1 was expressed in E. coli. GST-Bmh1
was immobilized on GSH beads and incubated with Cdh1-
FLAG. GST bound to GSH beads was used as a control. Acm1-
TAPwas immobilized on calmodulin beads and incubated with
Cdh1-FLAG. Empty calmodulin beads served as a control. Like-
wise, Acm1-TAPwas incubatedwithGST-Bmh1.We observed
stable interactions between Bmh1 and Cdh1, Acm1 and Cdh1,
and Acm1 and Bmh1 under high salt wash conditions (Fig. 1B).
To see if any one component of theCABcomplexwas necessary
for complex formation, we performed immunoprecipitations
from strains deleted for components of the complex. We
expressed N-terminally FLAG-tagged Cdh1 in WT, acm1,
bmh1, and bmh2 strains and immunopurified it with anti-
FLAG antibody followed by gel electrophoresis and mass spec-
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FIGURE 1. Acm1, Bmh1, and Cdh1 form a ternary complex. A, immunoprecipitations were performed with the yeast strain YKA154 containing Cdh1 with a
3FLAG epitope at the C terminus. The untagged parent strain was used as a control. Four liters of cells were grown to mid-log phase and arrested in G1 with
-factor. Once harvested, cells were lysed and subjected to antibody affinity pull-down assays using 100 l of the -FLAG antibody beads. Samples were run
on 4 –12% Bis-Tris gels (Invitrogen) and Coomassie -stained. From each lane, gel slices were excised throughout the entire length of the gel. Proteins in each gel
slice were digested with trypsin, analyzed by mass spectrometry, and identified through subsequent data base searching. Those proteins present in the sample
lane and absent in the control lane were considered to interact with Cdh1. Three proteins known as Bmh1, Bmh2, and a previously uncharacterized protein,
Acm1, were identified as Cdh1-interacting proteins. B, GST-Bmh1 from E. coli immobilized on 10 l of GSH beads or Acm1-TAP from 1 liter of asynchronous
yeast cells (A600  1) immobilized on 60 l of calmodulin affinity beads were used in the compact reaction columns for the respective binding assay. 10 l of
purified Cdh1-FLAG from 1 liter of asynchronous yeast cells or 10 l of purified GST-Bmh1 were incubated with the immobilized protein for 2 h at 4 °C and
washed extensively with high salt buffer. Bound proteins were eluted in 1 LDS buffer, run on 4 –12% Bis-Tris gels, and transferred to membranes for Western
analysis. I, FT, and E designate input, flow-through, and elution. GST immobilized on GSH beads or empty calmodulin beads were used as controls. The
immobilized protein shown is Coomassie-stained and is 20 greater than that shown in binding assay. Cdh1 bound to Bmh1 and Acm1, and Bmh1 bound to
Acm1. C, Cdh1, harboring an N-terminal 3FLAG epitope transcribed from the ADH promoter on a centromeric plasmid, was expressed by transforming the
plasmid into WT, acm1, bmh1, and bmh2 strains. Each strain was grown asynchronously in 1 liter of selective media to A600  1 before harvesting and
pulling down Cdh1 with 25 l of anti-FLAG M2 antibody-coupled resin (Sigma). Proteins were separated on a 4 –12% Bis-Tris gel and Coomassie-stained. *, gel
slices from each lane were excised in the region for which each protein migrates, digested with trypsin, and analyzed by mass spectrometry to detect the
presence of peptides corresponding to the proteins of interest. Neither Bmh1 nor Bmh2 could be detected in the acm1 strain. Bmh1 peptides could not be
detected in bmh1, but Acm1 and Bmh2 were present. Likewise, Bmh2 could not be detected in bmh2, but Acm1 and Bmh1 were present. D, Cdh1 was
purified from 2 liter of asynchronous cells grown to A600  1 from either WT or acm1 strains using 50 l of -FLAG antibody beads. GST-Bmh1 was immobilized
on 5 l of GSH beads in compact reaction columns. 2 l of FLAG-Cdh1 purified from WT and acm1 cells was incubated with the immobilized protein for 2 h
at 4 °C and washed extensively with high salt buffer. Bound proteins are eluted in 1 LDS buffer, run on 4 –12% Bis-Tris gels, and transferred to membranes for
Western analysis. An -FLAG antibody was used to detect the presence of Cdh1. The absence of Acm1 abolished the Bmh1-Cdh1 interaction.
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trometric analysis. Gel slices for each region where Cdh1,
Acm1, Bmh1, and Bmh2 migrate were analyzed. Bmh1 and
Bmh2 cannot be detected in the absence of Acm1. In the
bmh1 strain, Acm1 and Bmh2 still associated with Cdh1.
Likewise, Acm1 and Bmh1 still associated with Cdh1 in the
bmh2 strain (Fig. 1C). Additionally, we incubated purified
FLAG-Cdh1 from either wild-type or acm1 cells with immo-
bilized GST-Bmh1 in an in vitro binding assay.Without Acm1,
Cdh1 does not bind Bmh1 (Fig. 1D, lane 6). The Bmh1/Cdh1
binding in Fig. 1B is attributed to the presence of Acm1, which
co-purifies with Cdh1. Together these findings illustrate the
dependence of the CAB complex formation on Acm1 as well as
a possible redundancy between Bmh1 and Bmh2.
Acm1 Is Expressed in S Phase and Has an Effect on Cell Cycle
Progression—Because Cdh1 activates the APC in a cell cycle-
dependent manner, the interaction with Acm1 and the 14-3-3
proteins could also fluctuate throughout the cell cycle. To
determinewhether these proteinswere regulated in a cell cycle-
dependent manner, Acm1-TAP and Bmh1-TAP protein levels
were analyzed in cell lysates from G1, S, and M phase-arrested
cells. Acm1 levels were found to be significantly higher in S
phase over the other cell cycle phases, whereas Bmh1 levels
remain constant in each cell cycle stage (Fig. 2A). This finding is
in agreement with the Acm1 mRNA expression pattern
throughout the cell cycle (27). Analysis of Acm1mRNAexpres-
sion levels from the SaccharomycesGenome Database revealed
the closest pattern of gene expression to Acm1 is observed for
Clb5 (27). Clb5-Cdc28 is believed to be the primary cyclin-CDK
complex responsible for phosphorylation of Cdh1 during S
phase, although other G1 cyclin-CDK complexes are also
involved (15, 28, 29). Acm1 protein levels are highest in S phase
when Cdh1 is phosphorylated and APCCdh1 becomes inacti-
vated. This observation suggested an involvement of Acm1 in
phosphorylation-mediated regulation of APCCdh1 during S
phase.
We did not expect the deletion of ACM1 to induce large
perturbations in the cell cycle. According to the Saccharomyces
Genome Database, cells with ACM1 systematically deleted
FIGURE 2. Acm1 is expressed in S phase, and the deletion of Acm1 leads to
an enriched S-phase cell population. A, strains containing either Acm1 or
Bmh1 with a C-terminal TAP genomic tag were grown to mid-log phase and
arrested in G1 with -factor, S phase with hydroxyurea, and M phase with
nocodazole. Cells were harvested and lysed, and extracts were run on 4 –12%
Bis-Tris gels. Western analysis using an anti-Protein A antibody was per-
formed to measure protein levels in each cell cycle phase. Acm1 levels are
highest in S phase, whereas Bmh1 levels remain constant throughout the cell
cycle. B, cells from WT and acm1 strains were arrested with hydroxyurea for
synchronization and released into fresh media. Samples were collected in
20-min intervals for 100 min after release. DNA was stained using SYTOX
Green (Molecular Probes), and DNA content was measured on a FACScan
instrument for cell cycle progression. Time points for the FACS analysis are
present from 20 to 100 min. An enriched S phase population was observed at
80 min in the acm1 strain when compared with WT cells. Percentages of G1,
S, and G2/M cells for WT and acm1 strains at 80 min are shown. ModFit LT
software (Verity Software House, Inc.) was used to calculate percentages of
G1, S, and G2/M cells. C, cells from the acm1 strain (YKA323) containing the
plasmid pHLP117 expressing HA-Acm1 from its natural promoter or cells
from the same strain containing the empty plasmid were grown to mid-log
phase and arrested in G1 with -factor. Cells were released from the G1 arrest
by washing with 4 the culture volume (fresh media) and resuspending
washed cells in fresh media. Time points were taken in 15-min intervals. 40 g
of extract was loaded on the gels and probed with an -HA antibody or an
-Clb2 antibody. The Coomassie-stained membranes were used as loading
controls. A decrease in Clb2 levels is seen from time points 0 – 45 min in cells
lacking Acm1. FACS analysis was performed for each 15-min time point of the
G1 arrest and release.
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were viable (30). Indeed, acm1 cells grow at normal rate when
compared with WT cells. To see if deleting ACM1 had any
effect within a single cell cycle, cells from acm1 and wild-type
strains were synchronized in S phase with hydroxyurea,
released, and analyzed by flow cytometry for DNA content in
20-min intervals (Fig. 2B). Interestingly, FACS analysis of
acm1 cells showed an increase (14%) in the S phase cell pop-
ulation in comparison to wild-type cells at 80 min after release.
This effect was reproducible but to slightly varying degrees
(data not shown). Additionally, the acm1 strain resynchro-
nized withWT cells in M phase. The effect in S phase progres-
sion in acm1 cells suggests Acm1 may play a role in cell cycle
progression throughout S phase. If the CAB complex does play
a role in APCCdh1 regulation, one would expect a difference in
APCCdh1 substrate levels in cells lackingAcm1. To test whether
APCCdh1 substrates are affected in acm1 cells, we performed a
G1 block-release experiment in cells containing Acm1 com-
paredwith cells void ofAcm1 and examined levels of the known
APCCdh1 substrate Clb2. Interestingly, we found a slight
decrease in Clb2 levels in early time points in the absence of
Acm1 under certain growth conditions (Fig. 2C). The cycling
pattern of Clb2 corresponds to that of Acm1, although Acm1
increases to its maximum slightly before Clb2 reaches its high-
est level. An increased level of APCCdh1 activity in the strain
lacking Acm1 could explain this difference in Clb2 levels
between the two strains. However, the effects in the cell cycle
are slight, so CAB complex formation may exist as an overlap-
ping inhibitory mechanism in addition to phosphorylation for
APCCdh1.
CAB Complex Formation Inhibits APCCdh1-mediated Ubiq-
uitination of Clb2—Because Acm1 was predominantly
expressed in S phase when APCCdh1 activity is inhibited and
cells lacking Acm1 exhibited a difference in Clb2 levels, we
investigated whether the CAB complex formation affected
APCCdh1 activity directly. To demonstrate a possible inhibitory
effect of Acm1 and Bmh1 on APC activity, an in vitro ubiquiti-
nation assay was used to measure ubiquitination of the sub-
strate Clb2 (Fig. 3A). APC andTAP-taggedAcm1were purified
from yeast while Ubc4 (E2), Cdh1, and S35-labeled Clb2 were
expressed in vitro and incubated together for the assay. The
degree of substrate ubiquitination was measured by phospho-
rimaging analysis of S35-labeled Clb2. With Bmh1 levels held
constant, increasing concentrations of Acm1-TAP resulted in a
dose-dependent inhibition of Clb2 ubiquitination (lanes 3–5).
A mock purification from acm1 cells was used to rule out
buffer or nonspecific protein effects on APCCdh1 activity and
illustrates Clb2 ubiquitination levels without any inhibition
(lane 6). To quantify Acm1 inhibition relative toAPC andCdh1
levels, we used yeast purified FLAG-tagged APC, Cdh1, and
Acm1 (Fig. 3B). Acm1 appears to inhibit APC activity at subs-
toichiometric levels (Fig. 3B, lanes 5–7 and 10–12), although
we have observed stoichiometric binding from our gel-filtra-
tion data. We attribute this result to the presence of a certain
percentage of inactive Cdh1 in the preparation. No inhibitory
effect onClb2 ubiquitinationwas observed upon the addition of
Bmh1 alone (Fig. 3B, lane 4). This is not surprising due to the
requirement of Acm1 for the Bmh1-Cdh1 interaction. From
our in vitro ubiquitination assay results, we concludeAcm1 and
Bmh1 have an inhibitory effect on APCCdh1 ubiquitin ligase
activity.
To investigate whether Acm1 inhibits APCCdh1 activity in
vivo, we co-expressed Acm1 and the constitutively active Cdh1
mutant containing 9 of the 11 CDK phosphorylation sites
mutated to alanine. It has been previously shown that Cdh1
phosphomutants mimicking non-phosphorylated Cdh1 were
unable to accumulate Clb2 and Clb3, to form mitotic spindles,
and undergo cytokinesis (16). We found overexpression of
Acm1 rescues the lethality caused by overexpression of the
Cdh1 phosphomutant (Fig. 3C). From this experiment, we con-
cluded the CAB complex formation suppresses APCCdh1 activ-
ity as an overlapping regulatory mechanism in the absence of
complete CDK phosphorylation. This mechanism exists in
addition to Cdh1 phosphorylation, which has clearly been
shown to also inhibit APCCdh1 activity. CAB complex forma-
FIGURE 3. Acm1/Bmh1 inhibit APCCdh1 ubiquitin ligase activity by blocking Cdh1 binding to the APC. A, Cdh1, Ubc4, and Clb2 used in this assay were
produced in the TNT T7 Quick-coupled in vitro transcription/translation kit, and Clb2 was labeled with [35S]methionine. APC was purified from yeast and Bmh1
from E. coli. Acm1 was purified from 2 liters of asynchronous cells grown to A600  1 using 100 l of washed calmodulin resin. Resin was washed extensively
with APC-C buffer containing 1 mM CaCl2 and eluted in 2.5 mM EDTA buffer. 15 mM MgCl2 was added to the eluted Acm1 before use in the ubiquitination assay.
Components of the assay were mixed and incubated as described previously (22). Ubiquitination of Clb2 can be seen as bands of decreasing gel mobility. The
triangle represents increasing levels of Acm1. 1 Acm1 is the equivalent of 2 l or 1/50 from the EDTA elution. Acm1 inhibits APCCdh1 activity in a dose-de-
pendent manner. *, control purification from the acm1 strain equivalent to 4 concentration of Acm1 added. Levels of unconjugated Clb2 for the quanti-
tation of APCCdh1 inhibition by CAB complex formation are shown in the right panel. B, ubiquitination assay is the same as above with the exception of using
Cdh1 (p415ADH-FLAGCdh1 in YPL267W) and Acm1 (pHLP107 in YGL003) purified from yeast using FLAG immunoprecipitations for quantitation. Ubc4 and
Clb2 produced in the in vitro transcription/translation kit. Bmh1 levels used in the assay are sufficient to see by Coomassie staining. Levels of APC, Cdh1, and
Acm1 used in each assay can be seen in the lower panel. C, Cdh1 containing 9 of 11 CDK sites mutated to alanine was overexpressed through use of the GAL
promoter (pNC219-FLAGCdh1m9 in YKA323). In the same strain, pHLP106 expressing FLAG-Acm1 from the GAL promoter was also transformed. Cells were
plated on SD-Trp and grown for 48 h. Colonies were selected and plated on Raf-Trp, grown for 48 h, and replica-plated to Raf-Trp media containing galactose.
Extracts (40 g) were separated by SDS-PAGE and immunoblotted with -FLAG and PGK antibodies. Cdh1m9 overexpression is lethal when expressed without
Acm1 (section 5 and lane 5), but lethality is rescued by Acm1 overexpression (sections 6 and 7, lanes 6 and 7). Three colonies were tested to ensure each
contained both transformed plasmids. Sections 6 – 8 contain both plasmids, although section 8 exhibited low Cdh1m9 expression. Extract from the control
strain without plasmids present is shown in lane 9. D, bacterially expressed GST-Clb2 was incubated with FLAG-Cdh1 from acm1 cells for 30 min at 4 °C after
Cdh1 was preincubated with varying levels of Acm1. Clb2 was immobilized on affinity beads. GST bound to GSH beads and GST-Clb2 without Cdh1 were used
as controls. Following incubation with Cdh1, columns were washed extensively with high salt APC-C buffer and eluted with 1 LDS sample buffer. Samples
were run on a 4 –12% Bis-Tris gel and transferred for Western blot analysis. Immobilized protein shown is Coomassie-stained and is 20 greater than that
shown in binding assay. I, FT, and E designate input, flow through, and elution. Antibodies used for detection are as noted. Clb2 binding to Cdh1 decreases with
an increasing concentration of Acm1. E, N-terminally tagged FLAG-Cdh1 was purified from either WT or acm1 cells and incubated with APC via Apc1-TAP for
30 min at 4 °C. Empty calmodulin beads and APC-TAP without Cdh1 were used as controls. Following incubation with Cdh1, columns were washed extensively
with high salt APC-C buffer and eluted with 1 LDS sample buffer. Samples were run on a 4 –12% Bis-Tris gel and transferred for Western blot analysis.
Immobilized protein shown is Coomassie-stained and is 20 greater than that shown in binding assay. I, FT, and E designate input, flow through, and elution.
Antibodies used for detection are as noted. The presence of Acm1 has no effect on APC/Cdh1 binding.
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tion may function then to inhibit APCCdh1 regardless of the
phosphorylation status of Cdh1.
Our next question was how CAB complex formation inhib-
ited APCCdh1 activity. Enzymatic activity of APCCdh1 is medi-
ated by the interaction between Cdh1, APC, and the substrate.
Therefore, we hypothesized the complex either blocked APC
binding to Cdh1 or blocked Cdh1 binding to Clb2. To deter-
mine whether Acm1 and Bmh1 were inhibiting APCCdh1 activ-
ity by blocking the APC-Cdh1 interaction or by blocking sub-
strate binding to Cdh1, we performed binding assays between
Cdh1-APC and Cdh1-Clb2 with or without the presence of
the other complex components (Fig. 3, D and E). Bacterially
expressed GST-Clb2 was incubated with FLAG-Cdh1 from
acm1 cells after Cdh1 was preincubated with varying levels
of Acm1 in an in vitro binding assay. In the second in vitro
binding assay, N-terminally tagged FLAG-Cdh1 was purified
from WT and acm1 cells and incubated with APC via Apc1-
TAP. Although, no difference in Cdh1 binding to the APC
could be seen in the presence or absence of Acm1 (Fig. 3E,
compare lanes 13 and 17), Cdh1 binding to Clb2 decreased in a
dose-dependent manner with increasing levels of Acm1 (Fig.
3D, lanes 5–8). This observation suggests Acm1 disrupts the
interaction between the substrate andCdh1,whichmay explain
how CAB complex formation inhibits APCCdh1 activity.
Formation of theComplex Is Phosphorylation-dependent—Cur-
rentdata support the important roleCdh1phosphorylationplays
in the inactivation of APCCdh1 activity. Therefore, we hypoth-
esized phosphorylation had some involvement with the inter-
action between Cdh1, Acm1, and Bmh1. To determine what
role phosphorylation plays in the complex, we employed an in
vitro binding assay between Bmh1 and Cdh1 with and without
phosphatase treatment of Cdh1 (Fig. 4A). Cdh1-FLAG was
purified fromWT cells, treated with -phosphatase, and incu-
batedwith immobilizedGST-Bmh1 in an in vitro binding assay.
Cdh1-FLAG treated with phosphatase buffer but without
-phosphatase was used as a control. A shift in Cdh1 due to
dephosphorylation can be seen when run on a 7% Tris acetate
gel (Fig. 4A, lower panel). Upon phosphatase treatment, Cdh1
no longer interacted with Bmh1 (compare lanes 6 and 9). How-
ever, because Cdh1 was purified fromWT cells, Acm1 is pres-
ent. As shown previously, Acm1 is needed for the Cdh1-Bmh1
interaction. Acm1 contains five copies of the consensus CDK
recognition sequence ((S/T)PX(K/R)), and we have observed
that Acm1 is heavily phosphorylated in normal Cdh1 purifica-
tions from asynchronous cells. From this assay we could not
conclude whether the dephosphorylation of Cdh1, Acm1, or
both resulted in the diminished binding of Cdh1with Bmh1. To
determine whether phosphorylation of Cdh1 or Acm1 contrib-
ute to formation of the complex, we purified N-terminally
tagged FLAG-Cdh1 from acm1 cells and N-terminally tagged
HA-Acm1 from cdh1 cells and treated each with phosphatase
in an in vitro binding assay. Surprisingly, we found that phos-
phorylation is not needed for the interaction betweenCdh1 and
Acm1, and the addition of Bmh1 had little effect (Fig. 4B). To
determine whether Acm1 phosphorylation affects Bmh1 bind-
ing, an in vitro binding assay was employed with immobilized
GST-Bmh1 incubated with phosphatase-treated or untreated
FLAG-Acm1 from cdh1 cells. Dephosphorylation of Acm1
abolished binding to Bmh1 indicating that phosphorylation of
Acm1 but not Cdh1 is critical for the CAB complex formation
(Fig. 4C, lanes 4 and 8).
Phosphorylated Cdh1 Binds To and Activates the APC in
Vitro and Is Inhibited by Complex Formation—Knowing Acm1
has the ability to rescue lethality caused by expressing consti-
tutively active Cdh1 with 9 of the 11 CDK sites mutated to
alanine, we hypothesized partially phosphorylated Cdh1 could
still bind and activate theAPC. First, we investigatedwhether in
vivo phosphorylated Cdh1 could still bind to the APC in the
absence of the complex. To test this notion, we bound Cdh1 to
the APC in an in vitro binding assay and then used phosphatase
treatment on the complex to illustrate that all bound Cdh1 to
the APC is still partially phosphorylated. N-terminally tagged
FLAG-Cdh1 was purified from asynchronous acm1 cells and
incubated with yeast-purified APC via Apc1-TAP for 30min at
4 °C. After incubation with Cdh1, the immobilized APC/bound
Cdh1 was washed extensively and divided into two columns,
and one column was treated with -phosphatase. After treat-
ment, samples were separated by SDS-PAGE and analyzed by
Western blot. We found all Cdh1 bound to the APC was phos-
phorylated. Samples were run on a 6%Tris-glycine gel to differ-
entiate phosphorylated from dephosphorylated Cdh1. A clear
mobility shift due to dephosphorylation of bound Cdh1 can be
seen from untreated and phosphatase-treated samples (Fig.
5A). We believe the Cdh1 bound to the APC is only partially
phosphorylated due to the existing evidence that fully phospho-
rylated Cdh1 cannot bind or activate the APC (16, 18). This
suggests partial in vivo phosphorylation of Cdh1 in the absence
of the complex does not fully inhibit the interaction between
Cdh1 and the APC.
Because partial phosphorylation of Cdh1 did not disrupt the
interaction with the APC, we investigated whether the phos-
phorylated co-activator could activate the APC. From the pre-
vious experiments, we knew Cdh1 phosphorylation was not a
prerequisite for the interaction with Acm1. So, we also exam-
ined whether the addition of Acm1 and Bmh1 could attenuate
Clb2 ubiquitination using phosphorylated or nonphosphoryla-
ted Cdh1. To test this, we purified Cdh1 from acm1 cells,
divided the sample for dephosphorylation by phosphatase, and
used phosphorylated and dephosphorylated Cdh1 in the in
vitro ubiquitination assay (Fig. 5B). Cdh1 was washed exten-
sively to remove phosphatase prior to adding Cdh1 to the assay.
We added equivalent amounts ofCdh1 to both sets of reactions.
Both partially phosphorylated and dephosphorylated Cdh1
were sufficient for APC-mediated ubiquitin ligase activity
(lanes 3 and 8). Upon the addition of Acm1 and Bmh1, a
decrease in Clb2 ubiquitination can be seen using -phospha-
tase treated and untreated Cdh1 (lanes 4, 5, 9, and 10).
Although Cdh1 phosphorylation is not necessary for Acm1
binding and inhibition, Acm1 and Bmh1 may exist as an early
inhibition mechanism of partially phosphorylated Cdh1 before
the cyclin-dependent kinase can fully phosphorylate Cdh1 for
inactivation. Acm1 and Bmh1 may exist as an overlapping
inhibitory mechanism regardless of the phosphorylation status
of Cdh1 to ensure proper APC inactivation at the G1/S phase
transition and during S phase.
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DISCUSSION
Previous work has shown the phosphorylation of Cdh1
occurs at the end of G1 phase by the cyclin-dependent kinase
Cdc28 and has demonstrated that phosphorylation is responsi-
ble for the inactivation of the APCCdh1 complex (16, 18, 31).
Non-phosphorylatable Cdh1 mutants constitutively activate
FIGURE 4. Phosphorylation is involved in the assembly of the CAB com-
plex. A, an in vitro binding assay was used with C-terminally tagged Cdh1-
FLAG purified from WT cells (YKA154) and treated with -phosphatase. Phos-
phatase-treated and untreated Cdh1 was incubated with bacterially
expressed GST-Bmh1 immobilized on GSH affinity beads for 2 h at 4 °C. Once
Cdh1 was bound, columns were washed extensively with high salt APC-C
buffer and eluted with 1 LDS sample buffer. I, FT, and E designate input, flow
through, and elution. Phosphatase treatment of Cdh1 abolished Bmh1 bind-
ing. B, an in vitro binding assay was used with N-terminally tagged FLAG-Cdh1
and HA-Acm1 treated with -phosphatase. FLAG-Cdh1 was purified from 2
liters of asynchronous yeast cultures grown to A600  1 and incubated with
100 l of washed -FLAG resin. Resin was divided, and one half was treated
with phosphatase. Bound FLAG-Cdh1 was used as bait. HA-Acm1 was purified
from 2 liters of asynchronous cells grown to A600  1 and incubated with 50 l
of washed -HA resin. One half was treated with phosphatase and eluted 2
in 50 l of low salt APC-C buffer with HA peptide at 100 g/ml final concen-
tration. 1/20 of HA-Acm1 elution was used in each assay and allowed to incu-
bate for 1.5 h at 4 C. Once bound, the proteins were washed extensively with
high salt APC-C buffer. 40% of each reaction was loaded on the gel. A shift in
dephosphorylation of Acm1 can be seen in the lower panel. Empty -FLAG
beads were used as the control. Phosphorylation of Acm1 or Cdh1 has no
effect on their interaction with one another. C, an in vitro binding assay was
used with N-terminally tagged and bacterially expressed GST-Bmh1. GST and
GST-Bmh1 were prepared as described previously. N-terminally tagged
FLAG-Acm1 was purified from 2 liters of asynchronous yeast cultures grown
to A600  1, purified using 50 l of -FLAG resin, and one half treated with
-phosphatase. FLAG-Acm1 was eluted with FLAG peptide (250 g, final con-
centration) in 50 l of low salt APC-C buffer. Bound GST-Bmh1 (10 l of GSH
beads) was used as bait and incubated for 30 min at 4 °C with either phos-
phatase-treated or untreated FLAG-Acm1. 1/25 of FLAG-Acm1 elution was
used in each assay. Bound proteins were washed extensively with high salt
APC-C buffer and eluted in LDS sample buffer. 20% from each assay was
loaded on the gel. Nonphosphorylated Acm1 does not interact with Bmh1.
FIGURE 5. Phosphorylated Cdh1 is inhibited by complex formation.
A, N-terminally tagged FLAG-Cdh1 was purified from acm1 cells and
incubated with APC via Apc1-TAP immobilized on calmodulin beads. After
incubation with Cdh1, the immobilized APC/bound Cdh1 was washed exten-
sively and divided into two columns, and one was treated with -phospha-
tase. After treatment, samples were separated on a 6% Tris-glycine gel to
differentiate phosphorylated Cdh1 from unphosphorylated Cdh1 and ana-
lyzed by Western blot. Antibodies used for detection are as noted. Partially
phosphorylated Cdh1 can bind the APC. B, Ubc4 and Clb2 used in this assay
were produced by in vitro transcription/translation. N-terminally tagged
FLAG-Cdh1 was purified from 2 liters of asynchronous yeast cultures and
incubated with 50 l of -FLAG resin. The beads were divided and washed
extensively with APC-C buffer, and one half was treated with -phosphatase
for dephosphorylation. 1/50 of the FLAG-Cdh1 elution was used in each assay.
Acm1 was purified from 2 liters of asynchronous cells grown to A600  1 using
100 l of washed calmodulin resin. Resin was washed extensively with APC-C
buffer containing 1 mM CaCl2 and eluted in 2.5 mM EDTA buffer. 15 mM MgCl2
was added to the eluted Acm1 before use in the ubiquitination assay. The
triangle represents increasing levels of Acm1. 1 Acm1 is the equivalent of 2
l or 1/50 from the EDTA elution. Each reaction contains components desig-
nated by “” and “.” Components of the assay were mixed and incubated as
described previously. Ubiquitination of Clb2 can be seen as bands of decreas-
ing gel mobility. Partially phosphorylated Cdh1 activates the APC, and Acm1
and Bmh1 inhibit phosphorylated and nonphosphorylated Cdh1.
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the APC prohibiting cells from accumulating Clb2 and Clb3
(16). Additionally, in vitro phosphorylation of recombinant
Cdh1 is convincingly sufficient for inactivation of the APC (18).
There is no question phosphorylation of Cdh1 plays an impor-
tant role in APC inactivation. Because the cell cycle follows a
very strict schedule, proper and timely inactivation of the APC
must occur. Because Cdh1 has been shown to bind substrates
independent of the APC (9, 14, 32), one reason for the strict
regulation of Cdh1 may be to prevent the co-activator from
interferingwith substrates during parts of the cell cycle where it
is not needed. It is logical then that cells have overlapping inac-
tivation mechanisms to be sure certain cellular processes are
disabled. The possibility remains for novel proteins to exist for
APCCdh1 inactivation. Here, we have identified an additional
mechanism that acts independently of Cdh1 phosphorylation
to efficiently inhibit Cdh1 from activating the APC. The mech-
anism is composed of complex formation of Acm1 and Bmh1
with Cdh1 (CAB complex) and functions to inhibit APCCdh1
activity by blocking substrate binding to the co-activator. The
CAB complex is the first APCCdh1 inhibitor identified in yeast.
Acm1 is the critical component involved in complex formation
and is cell cycle-regulated. Hence, the Cdh1-Bmh1 interaction
is confined to the cell cycle interval during which Acm1 is
expressed.
We identified Acm1, Bmh1, and Bmh2 as Cdh1-interacting
proteins using Cdh1 immunoprecipitations. BMH1 and BMH2
appear to be functionally redundant, and although deletion of
both is lethal in most strains, cells remain viable with the dele-
tion of only one of the genes (33, 34). Bmh1 and Bmh2 are
members of the 14-3-3 class of proteins whose roles include
signal transduction, checkpoint control, apoptotic, and nutri-
ent-sensing pathways, as well as subcellular localization of
binding partners (26, 35). 14-3-3
proteins have been defined as phos-
phoserine-binding proteins with
ligands typically containing two dif-
ferent binding motifs, RSXpSXP or
RX(Y/F)XpSXP, although variations
of these motifs exist (25, 36). The
third member of the complex,
which forms with Cdh1, is a previ-
ously uncharacterized protein that
has been named Acm1. Acm1 has
been shown to interact with Bmh2
via yeast two-hybrid assays (37).
Acm1 has been identified as a
potential Cdc28 substrate and con-
tains five potential CDK phospho-
rylation sites that match the con-
sensus recognition sequence
(S/T)PX(K/R) (24). Interestingly,
the gene expression pattern of
Acm1 is similar to that of Clb5,
whose accumulation is necessary
for Cdh1 phosphorylation and S
phase entry. Although we have not
seen any significant sequence
homology of Acm1 in mammalian
species, the possibility remains an analog exists or that 14-3-3
proteins do not need an adaptor protein like Acm1 in higher
eukaryotes.
Inhibition of Cdh1must occur in a timelymanner for S phase
to proceed. The presence of Acm1 is therefore necessary at the
specific time when APCCdh1 needs to be inactivated. Indeed,
protein levels of Acm1 are highest in S phase coinciding with
the phosphorylation of Cdh1 byClb5-Cdc28. Deletion of Acm1
causes a perturbation in the cell cycle leading to an increased
population of cells in S phase. Currently, we cannot decipher
whether the increased S phase population is a result of early
entry into S phase or slower progression through S phase.
Additionally, we have observed slightly lower Clb2 levels in
acm1 cells after a G1 arrest and release suggesting an
increased APCCdh1 activity in the absence of Acm1. The
lower levels of Clb2 occurred in early time points under cer-
tain growth conditions. However, Clb2 levels return to a com-
parable level at later time points in the same experiment thatwe
attribute to effective inhibition ofAPCCdh1 by phosphorylation.
The cell cycle perturbation may not be explained by differing
Clb2 levels, but a longer S phase as a result of lower CDK activ-
ity could occur (38). However, our data can only suggest Acm1
has some regulatory role during S phase. Further experiments
are needed to determine whether levels of S phase cyclins differ
in acm1 cells.
Phosphorylation of Cdh1 occurs in S phase, and complete
phosphorylation disrupts the binding interface between Cdh1
and the APC. We have shown in vivo phosphorylated Cdh1
binds to and activates the APC, although this result can be
explained if Cdh1 is only partially phosphorylated. We have
demonstrated Acm1 and Bmh1 have a direct inhibitory effect
on APCCdh1 activity in vitro and in vivo and that inhibition by
FIGURE 6. Model of APCCdh1 inactivation. APCCdh1 is active throughout G1 phase until Cdh1 is phosphorylated by
the cyclin-dependent kinase Cdc28 at the G1/S phase transition. Additionally, a complex forms with the co-activator
consisting of Acm1 and Bmh1, which inhibits the APC at the end of G1. The CAB complex dissociates the substrate
from Cdh1 and acts independently of Cdh1 phosphorylation for the timely inactivation of the APC.
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Acm1 and Bmh1 can occur when Cdh1 is phosphorylated or
dephosphorylated. Although the phosphorylation status of
Cdh1 does not affect CAB complex formation, phosphorylation
of Acm1 plays a critical role in the assembly of the ternary
complex with Bmh1 and Cdh1. We have identified several
phosphopeptides within Acm1 from Cdh1 immunoprecipita-
tions. This is not surprising, because Acm1 was originally iden-
tified as a potential Cdc28 substrate (24). Dephosphorylation of
purified Acm1 has no effect on Cdh1 binding but does abolish
Bmh1 binding. Phosphorylation of Acm1 and Cdh1 may occur
in parallel by the same kinase to mediate complex formation.
We have also observed a slight shift in the gel mobility of Acm1
before it is degraded. The gel shift could be a result of dephos-
phorylation, which may play a role in Acm1 stability. Because
Bmh1 binds only phosphorylated Acm1 and has no inhibitory
role by itself, it may serve to protect Acm1 from early degrada-
tion.We are currently determiningwhether phosphorylation of
Acm1 is required for APCCdh1 inhibition and if it is involved in
Acm1 proteolysis.
We have not thoroughly explored the possibility of Acm1
and Bmh1 as novel APC substrates. Protein levels of Acm1
drop sharply after S phase when the APC is reactivated.
Although ACM1 mRNA expression drops after S phase, the
residual Acm1 left over may need to be removed to prevent
premature inhibition of APCCdh1. Proteasomal degradation
mediated by APCCdc20 would make sense to remove Acm1
until it is needed for APCCdh1 inactivation. The destruction
box (D box) and the KEN box have been identified as degrada-
tionmotifs in APC substrates (14), whereas Acm1 contains two
potential D boxes (RTIL at amino acid 8 andRIAL at amino acid
119) and a potential KENbox (KENLS at amino acid 98). Unlike
APC substrates, Bmh1 levels are abundant throughout the cell
cycle, and its levels do not fluctuate. Additionally, Bmh1 does
not interact with Cdh1 without Acm1 present. For these rea-
sons it is unlikely Bmh1 is an APC substrate. However, further
investigation is needed to determine the ultimate fate of these
proteins.
Interestingly, there appear to be some similarities between
the APCCdh1 inhibitor, Emi1, in higher eukaryotes and the
CAB complex in yeast. Both inhibit APCCdh1 activity in vitro
and directly bind Cdh1 (39). Emi1 and Acm1 are both pres-
ent during S phase and are degraded during M phase (40). In
a recent report, a model system has been proposed where Emi1
acts as a pseudosubstrate inhibitor of APCCdh1 and competes
with other D box-containing substrates for Cdh1 binding (41).
Although we have demonstrated Acm1 and Bmh1 block bind-
ing between Cdh1 and the APC substrate Clb2, we have not yet
determined which regions in Acm1 are involved in Cdh1 bind-
ing or if Acm1 mimics an APC substrate. We have observed an
interaction between Acm1 and C-terminal fragments of Cdh1
in gel-filtration experiments. The C terminus of Cdh1 houses a
WD-40 domain shown to be the site for substrate binding (9).
We can only speculate that, like Emi1, Acm1 could also mimic
Cdh1 substrates to inhibit APCCdh1. On the other hand, there is
no sequence similarity betweenEmi1 andAcm1outside of their
D box and KEN box regions. Thus, it is not clear whether these
Cdh1-associated proteins share the same inhibitory role
between species. We are currently exploring the mechanism of
inhibition of the CAB complex in greater detail.
Cdh1 has been shown to relocalize from the nucleus to the
cytoplasm removing it from the vicinity of the APC after phos-
phorylation presumably as a redundant inhibitory mechanism
(42). 14-3-3 proteins are involved in the relocalization of the cell
cycle regulatory protein Cdc25, so feasibly Acm1 and Bmh1
could play a similar role with Cdh1 (43, 44). However, the pos-
sibility of Acm1 and Bmh1 affecting Cdh1 localization has not
been thoroughly investigated.
Conceivably, additional mechanisms exist for APC inactiva-
tion through other protein interactions (45, 46). Our evidence
suggests that the complex formation serves as an overlapping
mechanism in addition to the phosphorylation message to effi-
ciently inhibit APCCdh1 activity prior to entering mitosis (Fig.
6). However, additional studies are required to further elucidate
the biological significance andmechanism by which CAB com-
plex formation inhibits APCCdh1.
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